Additionally in a study published in this issue, treatment of endogenous IDH1 mutant glioma cell lines with hypomethylating agent 5-aza-2'-deoxycytidine was found to drive differentiation in vitro [32]. The gene discussed is IDH1; the disease is central nervous system cancer.